Vedang Murthy presented results of the phase III BART trial at ASTRO24
Dr. Vedang Murthy, MD, is a Professor and Radiation Oncologist at Tata Memorial Hospital, Mumbai, specializing in urological cancers. He is an expert in advanced radiotherapy techniques, including IGRT and SBRT, with a focus on high-risk prostate cancer, kidney cancer, oligometastatic prostate cancer, and bladder preservation.
Murthy presented the results of the multicentric phase III bladder adjuvant RT (BART) trial at ASTRO24.
Authors: Vedang Murthy, Priyamvada Maitre, Ganesh Bakshi, Mahendra Pal, Maneesh Singh, Rakesh Sharma, Duleep Gudipudi, Lincoln Pujari, Himanshu Pandey, Bhavesh Bandekar, Deepa Joseph, Rahul Krishnatry, Reena Phurailatpam, Sadhana Kannan, Amandeep Arora, Ankit Misra, Amit Joshi, Vanita Noronha, Kumar Prabhash, Santosh Menon, and Gagan Prakash.
On this occasion, healthcare professionals and organizations shared on social media:
“Dr. Murthy stole the show at ASTRO2024 while raising the BAR(T)!
Vedang Murthy presenting results of the multicentric phase III bladder adjuvant RT (BART) trial ASTRO2024 with a punch of brilliance and flair!
And what’s more, with a simultaneous publication in IJROBP!”
“Tata Memorial Hospital continues to raise BART with another critical and practical study.
Vedang Murthy, TMC Radiation Oncology, Postop RT (bed + nodes) vs observation for high risk MIBC.
- Low acute toxicity.
- 10% (vs 8%) G3+ late toxicity
- 15% (vs 7%) G2 late toxicity.”
“Worried about toxicity with adjuvant RT post-cystectomy?
Vedang Murthy presents BART trial toxicity results. There is no significant difference. These are high risk patients, 70% had NAC. Paper in IJROBP.
Take home to surgeons/radoncs – Don’t worry!”
“We are honored to publish rapid online Dr. Vedang Murthy’s BART trial simultaneous with its presentation at Clinical Trials session today. Ballroom A/B/C now.
Editorial by Brian Baumann, Jason Efstathiou.
BART.
“Bladder adjuvant radiotherapy (BART): acute and late toxicity from a phase III multicenter randomized controlled trial. Presentation by Vedang Murthy, Tata Memorial Hospital. ASTRO24 written coverage by Rashid Sayyid, USC on UroToday.”
“Great talk by Vedang Murthy on bladder adjacent radiotherapy at ASTRO24 showing low toxicity rates. Conclusion: No need to be afraid!”
“ASTRO24 Clinical Trials
Vedang Murthy presents BART – largest RCT of adjuvant RT in bladder cancer.
Severe acute and late toxicity were low and similar between the two arms.
Ontological outcomes are awaited.”
“Vedang Murthy from TMC Radiation Oncology shows that adjuvant RT for high risk bladder cancer post-cystectomy is well tolerated. LRFS results eagerly awaited.”
“Vedang Murthy continues to raise the Bar(t) with randomised trials in GU Cast, radiotherapy trials. Adjuvant RT in high risk bladder cancer; 8-year accrual, with good safety signal (acute and late tox). Majority of patients had chemotherapy, pN+ve or T3+.”
More posts featuring ASTRO24 on oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023